Key Events This Week
Apr 13: Upgrade to Hold rating as technicals and financials improve
Apr 15: Stock jumps 5.00% amid strong volume
Apr 16: Continued gains with 4.99% rise
Apr 17: Death Cross formation signals potential bearish trend

Checkpoint Trends Ltd Forms Death Cross Signalling Potential Bearish Trend
2026-04-17 18:00:15Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has recently formed a Death Cross, a significant technical indicator where the 50-day moving average crosses below the 200-day moving average. This development signals a potential shift towards a bearish trend, raising concerns about the stock's medium to long-term momentum despite its recent volatile performance.
Read full news article
Checkpoint Trends Ltd Upgraded to Hold as Technicals and Financials Improve
2026-04-13 08:09:00Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating upgraded from Sell to Hold as of 10 April 2026. This change reflects a combination of improved technical indicators, robust financial performance, attractive valuation metrics, and a positive quality assessment, signalling a cautious but optimistic outlook for investors.
Read full news article
Checkpoint Trends Ltd Downgraded to Sell Amid Mixed Technicals and Valuation Concerns
2026-04-07 08:18:26Checkpoint Trends Ltd, a micro-cap player in the Pharmaceuticals & Biotechnology sector, has seen its investment rating downgraded from Hold to Sell as of 6 April 2026. This shift reflects a nuanced reassessment across four key parameters: quality, valuation, financial trend, and technicals, highlighting both strengths and emerging concerns in the company’s outlook.
Read full news article
Checkpoint Trends Ltd Valuation Shifts to Very Attractive Amid Market Volatility
2026-03-04 08:00:34Checkpoint Trends Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive rating, driven by improved price-to-earnings and price-to-book value metrics. This change comes amid a challenging market backdrop where the stock has underperformed the Sensex in the short term but continues to deliver exceptional long-term returns, prompting a reassessment of its price attractiveness relative to peers in the Pharmaceuticals & Biotechnology sector.
Read full news article







